---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-26-000006"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:21:04.554056+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Bionano Q4 2025 revenue $8.0M (-3% YoY); FY revenue $28.5M (-7%)

## Summary
- Q4 2025 revenue $8.0M vs $8.2M Q4 2024; consumables/software revenue down 1%.
- Full-year 2025 revenue $28.5M vs $30.8M FY2024; consumables/software up 7%.
- Q4 gross margin 43% (42% prior); non-GAAP gross margin also 43%.
- Operating expenses reduced 22% to $11.9M in Q4; installed base 387 systems (+4%).
- Company provided 2026 revenue outlook (specific figures not available in excerpt).

## SEC filing metadata
- accession: 0001411690-26-000006
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000006/0001411690-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169026000006/bngo-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-26-000006
- JSON: https://secwatch.observer/filing/0001411690-26-000006.json
- Plain text: https://secwatch.observer/filing/0001411690-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.